Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

(2017) George D. Demetri et al.   Journal of the National Comprehensive Cancer Network

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

(2011) Aurore Blesius et al.   BMC CANCER

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial

(2009) Axel Le Cesne et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis

(2008) John C. McAuliffe et al.   ANNALS OF SURGICAL ONCOLOGY

Molecular Pathobiology of Gastrointestinal Stromal Sarcomas

(2008) Christopher L. Corless et al.   Annual Review of Pathology-Mechanisms of Disease

Risk stratification of patients diagnosed with gastrointestinal stromal tumor

(2008) Heikki Joensuu   HUMAN PATHOLOGY

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

(2008) Burton L. Eisenberg et al.   JOURNAL OF SURGICAL ONCOLOGY

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)

(2007) Ronald P. DeMatteo et al.   CANCER